Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU

Gastric Cancer

Volumn 7, Issue 2, 2004, Pages 110-116

  Sakurai, Yoichi ^a   Uraguchi, Takashi ^a   Imazu, Hiroki ^a   Hasegawa, Shigeru ^a   Matsubara, Toshiki ^a   Ochiai, Masahiro ^a   Funabiki, Takahiko ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Dihydropyrimidine dehydrogenase; Gastric cancer; Nude mice; Thymidylate synthase

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STOMACH CANCER; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 3142559624     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-004-0280-9     Document Type: Article

References (35)

1. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. Cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;63:1459-73.
2. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
3. Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 2002;5(Suppl 1):17-22.
4. Cantrell JE, Hart RD, Taylor RF, Harvey JH Jr. Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 1987;71:615-8.
5. Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal carcinoma. J Clin Oncol 1990;8:313-8.
6. LoRusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius V. Low dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 1989;12:486-90.
7. Greenberg B, Ahmann F, Garewall H, Koopmann C, Coulthard S, Berzes H, et al. Neoadjuvant therapy for advanced head and neck cancer wtih allopurinol-modulated high dose 5-fluorouracil and cisplatin. Cancer 1987;59:1860-5.
8. Merlano M, Grimaldi A, Benasso M, Bacigalupo A, Toma S, Scarpati D, et al. Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. Am J Clin Oncol 1988;11:538-42.
9. Bernal AG, Cruz JJ, Sanchez P, Munoz A, Nieto A, Fonseca E, et al. Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. Cancer 1989;63:1927-30.
10. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 1986;83:8923-5.
11. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993;32:167-72.
12. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
13. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-70.
14. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-81.
15. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37.
16. Inada T, Ichikawa A, Kubota T, Ogata Y, Moossa AR, Hoffman RM. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res 1997;17:1965-71.
17. Geran RI, Greenberg NH, Schumacher AM, Abott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972;3:51-61.
18. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-6.
19. Spears CP, Gustavsson BG, Mitchell MS. Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984;44:4144-50.
20. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
21. Omura K, Kawakami K, Kanehira E, Nagasato A, Kawashima S, Tawaraya K, et al. The number of 5-fluoro-2′-deoxyuridine-5′-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment. Cancer Res 1995;55:3897-901.
22. Kashani-Sabet M, Rossi JJ, Lu Y, Ma JX, Chen J, Miyachi H, et al. Detection of drug resistance in human tumors by in vitro enzymatic amplifications. Cancer Res 1988;48:5775-8.
23. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30A:1517-22.
24. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
25. Sakurai Y, Yoshida I, Tonomura S, Sakai W, Nakamura Y, Imazu H, et al. Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma. Gastric Cancer 2003;6:243-9.
26. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
27. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
28. Ohtsu A, Boku N, Nagashima F, Koizumi W, Tanabe S, Saigenji K. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2001;20:656.
29. Suzuki M, Sekiguchi I, Sato I, Shirasaka T. Combined effects of S-1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats. Chemotherapy 1996;42:452-8.
30. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
31. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
32. Marunaka T, Minami Y, Umeno Y, Yasuda A, Sato T, Fujii S. Identification of metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) formed in vitro by rat liver microsomes. Chem Pharm Bull 1980;28:1780-95.
33. Fujii S, Nakamura Y, Takeda S, Morita K, Sato T, Marunaka T, et al. Metabolism, antitumor activity, and acute toxicity of 5-fluoro-1,3- bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione by oral administration to animals. Jpn J Cancer Res 1980;71:30-44.
34. Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996;88:668-74.
35. Takahashi A, Takagi M, Hishida H, Saji E, Takagi N, Amano H, et al. The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods. Jpn J Cancer Chemother 1987;14:2944-50.